Delcath Systems Inc (DCTH) Stock Price, Quote & News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal...

Industry: Medical Devices

Sector: Healthcare

Phone: 212 489 2100

Fax: 212 489 2102

Website: www.delcath.com

Address:

566 Queensbury Avenue, Queensbury, United States

alexpitti Apr. 20 at 8:56 PM

$DCTH while i may have convinced a few bulls here that $23.4 million consensus is too low for Q1, that's still the benchmark wall street cares about. if we beat that and get to $25 million, the stock should be fine. $27 million would be a huge beat. $29 million would push the stock to $16

0 · Reply

alexpitti Apr. 20 at 8:54 PM

we absolutely don't need $27 million. that would be a massive beat. we need at least $25 million. $DCTH

0 · Reply

actuallysam Apr. 20 at 4:21 PM

$DCTH So if a German lady has had 14 treatments coupled with history at Moffitt, surely other locations that went through all the hoops to get qualified do continuing due diligence on the product. This also leads me to think the phase 2 trials have an excellent chance at good results. Macroeconomics could hit the company hard, but that is the same with all companies.

1 · Reply

alexpitti Apr. 20 at 3:42 PM

$DCTH congratulations everyone. 21 out of 22 patients treated at moffitt with php are alive You helped make that happen

0 · Reply

actuallysam Apr. 20 at 2:02 PM

$DCTH So if Moffitt is doing so well, why is product still slow to gain traction? Ideally the quarter will approach $29 million.

2 · Reply

TangibleOne Apr. 18 at 6:15 PM

$DCTH took a position with SKM (ticker) for the Anthropic pre IPO exposure!

1 · Reply

Humdinger1966 Apr. 18 at 5:32 PM

$DCTH This is interesting, many of the Moffitt patients are now getting 7 or 8 treatments https://x.com/i/status/2030079184282996791

0 · Reply

Humdinger1966 Apr. 18 at 5:30 PM

$DCTH At the bottom of this image the Moffat researcher shows that, of the 22 patents treated since FDA approval, only 1 has died. https://x.com/jzager99/status/2023400461127348653/photo/2

0 · Reply

MildredBlackwella Apr. 18 at 10:27 AM

$OTH https://www.globenewswire.com/news-release/2026/04/16/3275540/0/en/Off-The-Hook-Yachts-Expands-Into-New-Boat-Sales-With-Sportsman-And-Phenom-Brands-Powered-By-Unique-Storage-Ecosystem.html $NB $DCTH Off The Hook Yachts Expands Into New Boat Sales With Sportsman And Phenom Brands, Powered By Unique Storage Ecosystem https://www.stocktitan.net/news/OTH/off-the-hook-yachts-expands-into-new-boat-sales-with-sportsman-and-aorktbng3ie4.html

0 · Reply

GioW Apr. 18 at 9:36 AM

$DCTH Sorry I see it now, Bruno posted on March 19th that OHSU on REMS website. At an average of about 1.7 procedures per month per site, I get somewhere between $26 and $27 million in revenue for Q1. At 26m. Market is at $23.41m, so at $26.4 m that is a revenue beat of 8.5%. at $28 m, that is a 20% beat. The stock has recovered a lot recently so not sure how the market reacts. Would $26 m impress the market? Possibly not. If the shares clear $11 with volume, then it probably goes to $14 easily if the guidance is bullish from Gerard.

1 · Reply

Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma

Apr 1, 2026, 8:30 AM EDT - 19 days ago

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Mar 3, 2026, 8:00 AM EST - 6 weeks ago

Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

Feb 26, 2026, 8:00 AM EST - 7 weeks ago

Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

Feb 12, 2026, 8:00 AM EST - 2 months ago

Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

Jan 27, 2026, 8:05 AM EST - 2 months ago

Delcath Systems to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 21, 2026, 4:01 PM EST - 3 months ago

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 9, 2026, 8:05 AM EST - 3 months ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Dec 31, 2025, 8:00 AM EST - 3 months ago

Delcath Systems Announces Publication of Subgroup Analyses of the Phase 3 FOCUS Study of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma

Dec 3, 2025, 4:01 PM EST - 4 months ago

Delcath Systems Announces Publication of 10-Year Single-Center Experience with Percutaneous Hepatic Perfusion in Liver-Dominant Metastatic Uveal Melanoma

Nov 20, 2025, 4:01 PM EST - 5 months ago

Delcath Systems Board of Directors Authorizes $25 Million Share Repurchase Program

Nov 18, 2025, 8:00 AM EST - 5 months ago

Delcath Systems Announces Publication of Expert Narrative Review on Percutaneous Hepatic Perfusion for Liver Metastases from Uveal Melanoma

Nov 13, 2025, 8:30 AM EST - 5 months ago

Delcath Systems Announces Publication of Real-World Evidence Supporting Early Use of Liver-Directed Therapy with PHP in Achieving Long-Term Survival for Metastatic Uveal Melanoma Patients

Nov 6, 2025, 4:01 PM EST - 5 months ago

Delcath Systems to Participate in Upcoming Investor Conferences

Nov 4, 2025, 8:00 AM EST - 5 months ago

Delcath Systems Reports Third Quarter 2025 Results and Business Highlights

Oct 21, 2025, 8:30 AM EDT - 6 months ago

Delcath Systems to Host Third Quarter 2025 Earnings Call

Oct 18, 2025, 4:15 PM EDT - 6 months ago

Delcath Systems Announces Preliminary Third Quarter 2025 Financial Results

Oct 18, 2025, 4:13 PM EDT - 6 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint

Sep 22, 2025, 4:01 PM EDT - 7 months ago

Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress

Aug 19, 2025, 8:30 AM EDT - 8 months ago

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Aug 6, 2025, 8:00 AM EDT - 9 months ago

Delcath Systems Reports Second Quarter 2025 Results and Business Highlights

Jul 29, 2025, 4:01 PM EDT - 9 months ago

Delcath Systems to Participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 23, 2025, 4:01 PM EDT - 9 months ago

Delcath Systems to Host Second Quarter 2025 Earnings Call

May 22, 2025, 7:00 AM EDT - 11 months ago

Delcath Systems Issues Full Year 2025 Guidance

May 15, 2025, 4:30 PM EDT - 1 year ago

Delcath Systems to Participate at the Craig-Hallum 22nd Annual Investor Conference

May 9, 2025, 5:30 PM EDT - 1 year ago

Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 8, 2025, 7:30 AM EDT - 1 year ago

Delcath Systems Reports First Quarter 2025 Results and Business Highlights

Apr 28, 2025, 8:30 AM EDT - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Apr 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Host First Quarter 2025 Earnings Call

Apr 9, 2025, 5:00 PM EDT - 1 year ago

Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma

Mar 24, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 14, 2025, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mar 6, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Reports Fourth Quarter and Full Year 2024 Results

Feb 20, 2025, 8:30 AM EST - 1 year ago

Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call

Feb 14, 2025, 8:30 AM EST - 1 year ago

Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Jan 30, 2025, 7:06 PM EST - 1 year ago

Biotech walks a 'tightrope' amid unclear funding, regulations

ELVN IBB

Jan 28, 2025, 4:01 PM EST - 1 year ago

Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 13, 2025, 8:00 AM EST - 1 year ago

Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

Jan 3, 2025, 4:01 PM EST - 1 year ago

Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises

Dec 2, 2024, 8:30 AM EST - 1 year ago

Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer

Nov 8, 2024, 8:00 AM EST - 1 year ago

Delcath Systems Reports Third Quarter 2024 Results and Business Highlights

Oct 25, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems to Host Third Quarter 2024 Earnings Call

Oct 17, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients

Aug 28, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress

alexpitti Apr. 20 at 8:56 PM

0 · Reply

alexpitti Apr. 20 at 8:54 PM

we absolutely don't need $27 million. that would be a massive beat. we need at least $25 million. $DCTH

0 · Reply

actuallysam Apr. 20 at 4:21 PM

1 · Reply

alexpitti Apr. 20 at 3:42 PM

$DCTH congratulations everyone. 21 out of 22 patients treated at moffitt with php are alive You helped make that happen

0 · Reply

actuallysam Apr. 20 at 2:02 PM

$DCTH So if Moffitt is doing so well, why is product still slow to gain traction? Ideally the quarter will approach $29 million.

2 · Reply

TangibleOne Apr. 18 at 6:15 PM

$DCTH took a position with SKM (ticker) for the Anthropic pre IPO exposure!

1 · Reply

Humdinger1966 Apr. 18 at 5:32 PM

$DCTH This is interesting, many of the Moffitt patients are now getting 7 or 8 treatments https://x.com/i/status/2030079184282996791

0 · Reply

Humdinger1966 Apr. 18 at 5:30 PM

$DCTH At the bottom of this image the Moffat researcher shows that, of the 22 patents treated since FDA approval, only 1 has died. https://x.com/jzager99/status/2023400461127348653/photo/2

0 · Reply

MildredBlackwella Apr. 18 at 10:27 AM

0 · Reply

GioW Apr. 18 at 9:36 AM

1 · Reply

GioW Apr. 18 at 9:04 AM

$DCTH I've not looked at the Hepzato websites for a while. At least a month. When exactly did Oregon Health Sciences University Hospital in Portland go onto the REMS website? Did anyone see it at the time? It went on the main website in October but when was it added to the REMS website?

0 · Reply

alexpitti Apr. 18 at 4:04 AM

$DCTH i modeled ending the year with 38.5 sites and the average for the year being 32.5 which is fair i think

0 · Reply

brunoq14 Apr. 17 at 8:33 PM

$DCTH Regional One Health, Memphis, TN REMS site #30

3 · Reply

DragonAlgo Apr. 17 at 11:06 AM

🐉 $DCTH CALL — DragonAlgo® Signal Contract: DCTH CALL Expiry: 2026-04-17 | Strike: $10.00 | Type: CALL Option Plan (premium): Entry: $0.88 Stop: $0.63 TP1: $1.14 TP2: $1.50 TP3: $2.11 🔗 https://dragonalgo.com

0 · Reply

DragonAlgo Apr. 15 at 7:58 PM

🐉 $DCTH CALL — DragonAlgo® Signal Contract: DCTH CALL Expiry: 2026-04-17 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $3.55 Stop: $2.56 TP1: $4.62 TP2: $6.03 TP3: $8.52 🔗 https://dragonalgo.com

0 · Reply

DragonAlgo Apr. 15 at 5:40 AM

🐉 $DCTH CALL — DragonAlgo® Signal Contract: DCTH CALL Expiry: 2026-04-17 | Strike: $12.50 | Type: CALL Option Plan (premium): Entry: $0.02 Stop: $0.01 TP1: $0.03 TP2: $0.03 TP3: $0.05 🔗 https://dragonalgo.com

0 · Reply

alexpitti Apr. 15 at 2:17 AM

$DCTH $116 million bear case $127 million base case and $140 million bull case 2026 sales. but the consensus is $103

2 · Reply

alexpitti Apr. 14 at 4:31 PM

$DCTH on october 15th, nice will upgrade chemosat from special arrangements to full aprpvoal. this will be the first change since april 2021

0 · Reply

ManyThanks212 Apr. 14 at 1:35 PM

$DCTH drop your PT

2 · Reply

alexpitti Apr. 14 at 4:05 AM

$DCTH the nice decision will be published 4-6 weeks after the april 16th meeting which means in late may we will know

1 · Reply

Value1008 Apr. 14 at 1:46 AM

$DCTH - Nice to see shareprice close above the 200dma on daily chart. First time that's happened since stock began its plunge from upper teens last June-July.

1 · Reply

Polaris2024 Apr. 13 at 11:58 PM

$DCTH Highlighted today at conference and will be highlighted twice on Wednesday. Good volume and getting traction. This could blow upwards quickly so goodbye to the shorts that have dragged this down to long.

1 · Reply

Market Cap	374.18M
Revenue (ttm)	85.23M
Net Income (ttm)	2.70M
EPS (ttm)	N/A
PE Ratio	154.71
Forward PE	N/A
Profit Margin	3.17%
Debt to Equity Ratio	0.00

Volume	342,100
Avg Vol	409,910
Day's Range	N/A - N/A
Shares Out	34.46M
Stochastic %K	86%
Beta	0.44
Analysts	Strong Sell
Price Target	$21.67